KR101280481B1 - Cosmetic for Improving Skin Wrinkle Comprising polyphosphate of fermented peppermint. - Google Patents
Cosmetic for Improving Skin Wrinkle Comprising polyphosphate of fermented peppermint. Download PDFInfo
- Publication number
- KR101280481B1 KR101280481B1 KR1020100051457A KR20100051457A KR101280481B1 KR 101280481 B1 KR101280481 B1 KR 101280481B1 KR 1020100051457 A KR1020100051457 A KR 1020100051457A KR 20100051457 A KR20100051457 A KR 20100051457A KR 101280481 B1 KR101280481 B1 KR 101280481B1
- Authority
- KR
- South Korea
- Prior art keywords
- peppermint
- extract
- cosmetic
- fermentation extract
- skin
- Prior art date
Links
- 244000246386 Mentha pulegium Species 0.000 title claims abstract description 64
- 235000016257 Mentha pulegium Nutrition 0.000 title claims abstract description 64
- 235000004357 Mentha x piperita Nutrition 0.000 title claims abstract description 64
- 235000001050 hortel pimenta Nutrition 0.000 title claims abstract description 64
- 239000002537 cosmetic Substances 0.000 title claims abstract description 46
- 230000037303 wrinkles Effects 0.000 title claims abstract description 19
- 229920000388 Polyphosphate Polymers 0.000 title description 3
- 239000001205 polyphosphate Substances 0.000 title description 3
- 235000011176 polyphosphates Nutrition 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 54
- 238000000855 fermentation Methods 0.000 claims abstract description 45
- 230000004151 fermentation Effects 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000011574 phosphorus Substances 0.000 claims abstract description 14
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 14
- 235000020737 peppermint extract Nutrition 0.000 claims abstract description 12
- 241000186660 Lactobacillus Species 0.000 claims abstract description 6
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 5
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 22
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 22
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 25
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000009759 skin aging Effects 0.000 abstract description 6
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 34
- 239000000203 mixture Substances 0.000 description 33
- 210000003491 skin Anatomy 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 230000007794 irritation Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 206010015150 Erythema Diseases 0.000 description 11
- 231100000321 erythema Toxicity 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 9
- 230000008929 regeneration Effects 0.000 description 9
- 238000011069 regeneration method Methods 0.000 description 9
- 239000002085 irritant Substances 0.000 description 8
- 231100000021 irritant Toxicity 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 102000016942 Elastin Human genes 0.000 description 7
- 108010014258 Elastin Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 229920002549 elastin Polymers 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229910052785 arsenic Inorganic materials 0.000 description 6
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 229910001385 heavy metal Inorganic materials 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- RODZIAKMFCIGPL-UHFFFAOYSA-N P.I.I Chemical compound P.I.I RODZIAKMFCIGPL-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004177 elastic tissue Anatomy 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- -1 peptidyl carbamates Chemical class 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010058667 Oral toxicity Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 231100000418 oral toxicity Toxicity 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000007805 zymography Methods 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000048246 Gallicrex cinerea Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 241000227166 Harrimanella hypnoides Species 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 108010084315 endopolyphosphatase Proteins 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 108091023030 exopolyphosphatase Proteins 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000002602 strong irritant Substances 0.000 description 1
- 150000008054 sulfonate salts Chemical class 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품에 관한 것으로서, 더욱 상세하게는 박하를 즉시 동결건조한 뒤, 100 내지 200℃ 추출온도에서 약 2 시간 동안 열수 추출하여 여과한 다음 50 내지 70℃에서 감압농축하고 정제하는 단계 및 락토바실러스 애시도필러스를 이용하여 상기 수득된 박하 추출물을 배양하여 박하 발효액을 제조하는 단계를 통해 제조된 박하 발효 추출물을 화장품에 함유시켜 피부 노화 억제가 높아 주름 개선 효과가 뛰어난 화장품을 제공하는 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품에 관한 것이다.
본 발명을 통해 제조된 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품은 피부 노화 억제하는 효과가 우수하므로 피부 주름개선에 유용하게 사용될 수 있다.The present invention relates to a functional cosmetic for improving skin wrinkles containing an inpolymer contained in the peppermint fermentation extract as an active ingredient, more specifically, after lyophilizing the peppermint immediately, hot water for about 2 hours at an extraction temperature of 100 to 200 ℃ Extracting and filtering, then concentrated under reduced pressure at 50 to 70 ℃ and purified and the peppermint fermentation extract prepared by the step of cultivating the obtained peppermint extract using Lactobacillus ashdophyllus to prepare a peppermint fermentation broth to cosmetics It relates to a functional cosmetics for improving skin wrinkles containing the phosphorus as an active ingredient contained in the peppermint fermentation extract to provide a cosmetic with excellent anti-wrinkle effect by high skin aging inhibition.
Functional cosmetics for improving skin wrinkles containing the inpolymer contained in the peppermint fermentation extract prepared through the present invention as an active ingredient is excellent in the effect of inhibiting skin aging can be usefully used for skin wrinkle improvement.
Description
본 발명은 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품에 관한 것으로서, 더욱 상세하게는 박하를 즉시 동결건조한 뒤, 100 내지 200℃ 추출온도에서 약 2 시간 동안 열수 추출하여 여과한 다음 50 내지 70℃에서 감압농축하고 정제하는 단계 및 락토바실러스 애시도필러스를 이용하여 상기 수득된 박하 추출물을 배양하여 박하 발효액을 제조하는 단계를 통해 제조된 박하 발효 추출물을 화장품에 함유시켜 피부 노화 억제가 높아 주름 개선 효과가 뛰어난 화장품을 제공하는 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품에 관한 것이다.
The present invention relates to a functional cosmetic for improving skin wrinkles containing an inpolymer contained in the peppermint fermentation extract as an active ingredient, more specifically, after lyophilizing the peppermint immediately, hot water for about 2 hours at an extraction temperature of 100 to 200 ℃ Extracting and filtering, then concentrated under reduced pressure at 50 to 70 ℃ and purified and the peppermint fermentation extract prepared by the step of cultivating the obtained peppermint extract using Lactobacillus ashdophyllus to prepare a peppermint fermentation broth to cosmetics It relates to a functional cosmetics for improving skin wrinkles containing the phosphorus as an active ingredient contained in the peppermint fermentation extract to provide a cosmetic with excellent anti-wrinkle effect by high skin aging inhibition.
피부탄력은 진피층에 존재하는 엘라스틴(elastin)으로 구성된 탄력섬유에 의해 나타나는데, 이러한 탄력섬유는 고무와 같이 매우 낮은 탄성계수를 가지고 있어서, 작은 힘에 의해서도 쉽게 변형되고, 또 그 힘이 제거되었을 때는 쉽게 원형으로 되돌아온다. Skin elasticity is represented by elastic fibers composed of elastin in the dermis, which has a very low modulus of elasticity, such as rubber, which is easily deformed by small forces and easily removed when the forces are removed. Return to the circle.
또한, 탄력섬유는 엘라스틴이라는 무정형의 기질에 미원섬유(microfibrils)들이 박혀 있는 형태를 띠고 있는데 엘라스틴은 라이신에서 유래한 데스모신(desmosine)과 아이소데스모신(isodesmosine)이라는 탄력섬유에서만 발견되는 아주 톡특한 아미노산으로 구성된 단백질이다. In addition, elastic fibers have a form in which microfibrils are embedded in an amorphous matrix called elastin, which is a very unique feature found only in elastic fibers called desmosine and isodesmosine derived from lysine. A protein composed of amino acids.
이러한 데스모신과 아이소데스모신 등은 긴 펩타이드 사슬안에서 가교(cross-link)를 형성하고 있는데, 이러한 구조가 엘라스틴으로 하여금 고무와 같은 성질을 갖게 한다. 또한, 엘라스틴으로 구성된 탄력섬유는 콜라겐(collagen)이라고 하는 교원섬유와 함께 존재하는데, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부 탄력유지가 가능하다.Desmosin and isodesmosin form cross-links in long peptide chains, which make elastin rubbery. In addition, the elastic fiber composed of elastin is present along with collagen fibers called collagen, which is sufficient to maintain skin elasticity in a state where elastin and collagen are sufficiently present.
피부 탄력저하는 노화와 자외선 등에 의한 피부세포(섬유아세포)의 약화로 엘라스틴의 생성저하 및 파괴에 의해 유발되는데, 자외선 등에 의해 피부내에 엘라스틴 분해효소가 발현되며 이 효소는 피부내의 정상적인 엘라스틴을 분해하여 피부 탄력 저하를 가져온다. Decreased elasticity of the skin is caused by aging and degeneration of skin cells (fibroblasts) due to ultraviolet rays, etc., which causes elastin degradation and destruction. Elastin degrading enzymes are expressed in the skin by ultraviolet rays. It causes a decrease in skin elasticity.
또한, 피부 탄력저하는 피부 진피의 70% 이상을 구성하는 콜라겐이라는 단백질의 손상 및 생성저하에 의해서도 발생된다. Decreased skin elasticity is also caused by damage to and production of a protein called collagen, which makes up more than 70% of the skin dermis.
콜라겐 역시 자외선 등에 의해 유발되는 콜라게나제(collagenase)라는 분해효소에 의해 분해된다.Collagen is also broken down by a degrading enzyme called collagenase, which is caused by ultraviolet light.
한편, 레구미노사 종자(Leguminosae seed)에서 얻어진 단백질 분획은 탄력증대효과를 나타내며(미국특허 제5,322,839호), 맥아 추출물(malt extract) 등을 포함하는 조성물은 콜라게나제(collagenase)의 활성을 억제하는데 응용되고 있다.On the other hand, the protein fraction obtained from Leguminosae seed (El Patent No. 5,322,839) exhibits an elasticity increasing effect, the composition comprising malt extract (malt extract) and the like to inhibit the activity of collagenase (collagenase) It is applied.
콜라게나제 또는 엘라스티나제의 억제제로는 카르바민산 펩티드(peptidyl carbamates), 티오카르바민산 펩티드(peptidyl thiocarbamates), 하이드록사메이트(hydroxamates), 세팔로스포린(cephalosporins), 설포산염(sulphonate salts) 등을 함유하는 화장료 조성물(미국특허 제5,614,489호) 등이 보고되어 있다. Inhibitors of collagenase or elastinase include peptidyl carbamates, peptidyl thiocarbamates, hydroxamates, cephalosporins, and sulfonate salts. Cosmetic compositions (US Pat. No. 5,614,489) and the like have been reported.
그러나, 이러한 종래의 보고에서는 피부탄력증대 효과를 나타내기 위해 단순히 콜라게나제의 활성을 억제시키거나 또는 엘라스티나제의 활성을 억제한 것으로, 그 효과가 진피층에 한정되어 있다는 한계가 있다.However, in the conventional report, in order to show skin elasticity-enhancing effect, it merely inhibits the activity of collagenase or inhibits the activity of elastinase, and the effect is limited to the dermal layer.
본 발명에서 설명하고 있는 박하(Mentha arvensis var. piperascens)는 쌍떡잎식물 통화식물목 꿀풀과의 여러해살이 숙근초로서, 주요성분이 알파-피넨(alpha-pinene(+, -)), 아니스알데히드(anisaldehyde), 다우코스테롤(Daucosterol), 유제놀(Eugenol), 리날롤(Linalool), 멘톤(Menthone), (+)-네오멘톨((+)-Neomenthol) 등이고, 피부의 점막과 혈관을 수축하는 작용, 신경말초를 마비시키는 작용, 통증을 멎게 하는 작용, 소양감을 멈추게 하는 작용이 있어서 피부에 특유의 청량감을 주어 피부병을 개선하고 피부진정작용과 항산화효과가 있다.
Peppermint (Mentha arvensis var. Piperascens) described in the present invention is a perennial root of perennial herb of dicotyledons and moss plants. , Doucosterol, eugenol, linalol, menthone, (+)-neomenthol ((+)-neomenthol), and contraction of skin mucous membranes and blood vessels, It has the effect of numbing the nerves, stopping the pain, stopping the pruritus, giving the skin a unique refreshing feeling, improving skin disease and having a soothing and antioxidant effect.
따라서 본 발명은 상기와 같은 종래 기술의 문제점을 감안하여 제안된 것으로서, 본 발명의 목적은 본 발명의 목적은 피부 노화 억제가 높아 주름 개선 효과가 뛰어난 박하 발효 추출물을 제공하는 것이다.Accordingly, the present invention has been proposed in view of the problems of the prior art as described above, and an object of the present invention is to provide a peppermint fermentation extract having a high anti-wrinkle effect due to high skin aging inhibition.
본 발명의 다른 목적은 상기 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품을 제공하는 것이다.
Another object of the present invention to provide a functional cosmetics for improving skin wrinkles containing the phosphorus as an active ingredient contained in the peppermint fermentation extract.
본 발명이 해결하고자 하는 과제를 달성하기 위하여,In order to achieve the object of the present invention,
본 발명의 일실시예에 따른 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품은,Functional cosmetics for improving skin wrinkles containing the phosphorus as an active ingredient contained in the peppermint fermentation extract according to an embodiment of the present invention,
박하를 재료의 표면에 존재하는 이물질 등을 제거하기 위하여 세척한 다음 박하를 동결건조시키는 동결건조단계와;A lyophilization step of washing the mint to remove foreign substances, etc. present on the surface of the material, and then lyophilizing the mint;
상기 동결 건조된 박하를 50메쉬 이상의 분말 상태로 분쇄하는 분쇄단계와; Grinding the freeze-dried peppermint into a powder state of 50 mesh or more;
상기 분말화된 박하를 증류수에 넣고, 100 내지 200℃ 추출온도에서 약 2 시간 동안 열수 추출하는 열수추출단계와;Putting the powdered mint in distilled water and extracting hot water for about 2 hours at an extraction temperature of 100 to 200 ° C .;
여과된 박하 추출물을 50 내지 70℃에서 감압농축하고 최종 농축액을 수득하는 감압농축단계와;Concentration of the filtered peppermint extract under reduced pressure at 50 to 70 ° C. to obtain a final concentrate;
락토바실러스 애시도필러스를 이용하여 상기 수득된 박하 추출물을 배양하여 박하 발효액을 제조하는 단계;에 의해 제조된 박하 발효 추출물을 이용하여 제조된다.It is prepared using the peppermint fermentation extract prepared by culturing the obtained peppermint extract using Lactobacillus ashdophyllus to prepare a peppermint fermentation broth.
상기에서 살펴본 바와 같이, 본 발명의 박하 발효 추출물은 피부 노화 억제하는 효과가 우수하므로 피부 주름개선에 유용하게 사용될 수 있다.
As described above, the peppermint fermentation extract of the present invention has an excellent effect of inhibiting skin aging, and thus may be usefully used for skin wrinkle improvement.
도 1은 세포재생효과를 나타낸 도면이다.
도 2는 단백질 분해효소 억제 시험(MMP-2)의 결과를 나타낸 도면이다.
도 3은 단백질 분해효소 억제 시험(MMP-1)의 결과를 나타낸 도면이다.1 is a view showing the cell regeneration effect.
2 shows the results of the protease inhibition test (MMP-2).
3 shows the results of the protease inhibition test (MMP-1).
상기 과제를 달성하기 위한 본 발명인 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품은,Functional cosmetics for improving skin wrinkles containing the phosphorus contained in the peppermint fermentation extract of the present invention for achieving the above object,
박하를 재료의 표면에 존재하는 이물질 등을 제거하기 위하여 세척한 다음 박하를 동결건조시키는 동결건조단계와;A lyophilization step of washing the mint to remove foreign substances, etc. present on the surface of the material, and then lyophilizing the mint;
상기 동결 건조된 박하를 50메쉬 이상의 분말 상태로 분쇄하는 분쇄단계와; Grinding the freeze-dried peppermint into a powder state of 50 mesh or more;
상기 분말화된 박하를 증류수에 넣고, 100 내지 200℃ 추출온도에서 약 2 시간 동안 열수 추출하는 열수추출단계와;Putting the powdered mint in distilled water and extracting hot water for about 2 hours at an extraction temperature of 100 to 200 ° C .;
여과된 박하 추출물을 50 내지 70℃에서 감압농축하고 최종 농축액을 수득하는 감압농축단계와;Concentration of the filtered peppermint extract under reduced pressure at 50 to 70 ° C. to obtain a final concentrate;
락토바실러스 애시도필러스를 이용하여 상기 수득된 박하 추출물을 배양하여 박하 발효액을 제조하는 단계;로 제조된 박하 발효 추출물을 이용하여 제조된다.It is prepared using the peppermint fermentation extract prepared by culturing the obtained peppermint extract using Lactobacillus ashdophyllus to prepare a peppermint fermentation broth.
이때, 상기 박하 발효 추출물의 함량은,At this time, the content of the peppermint fermentation extract,
화장품 총 중량을 기준으로 0.001 내지 50중량부인 것을 특징으로 한다.It is characterized in that 0.001 to 50 parts by weight based on the total weight of the cosmetic.
이때, 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품은, At this time, the functional cosmetics for improving skin wrinkles containing the phosphorus contained in the peppermint fermentation extract as an active ingredient,
유화 제형의 영양화장수, 크림, 에센스 및 가용화 제형의 유연화장수로 구성된 군으로부터 선택되는 제형을 갖는 것을 특징으로 한다.It is characterized by having a formulation selected from the group consisting of nutritive cosmetics, creams, essences and softening cosmetics of solubilized formulations.
이때, 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품은,At this time, the functional cosmetics for improving skin wrinkles containing the phosphorus contained in the peppermint fermentation extract as an active ingredient,
화장품 총 중량을 기준으로 인중합체가 0.0001 내지 10 중량부인 것을 특징으로 한다.The polymer is 0.0001 to 10 parts by weight based on the total weight of the cosmetic.
이때, 박하 발효 추출물에 함유된 인중합체의 0.0001 내지 10 중량부를 포함한 유화 제형의 영양화장수, 크림, 에센스 및 가용화 제형의 유연화장수로 구성된 군으로부터 선택되는 제형을 갖는 것을 특징으로 한다.At this time, it is characterized in that it has a formulation selected from the group consisting of nutrient cosmetics, creams, essences and softening of the solubilized formulation of the emulsion formulation containing 0.0001 to 10 parts by weight of the phosphorus contained in the peppermint fermentation extract.
화장품 산업분야에서 주목해야할 부분은 주름개선, 미백, 자외선 차단 분야이다.Of note in the cosmetics industry are wrinkle improvement, whitening and sun protection.
이에 각종 천연물들이 이용되고 있는 실정이다.This is a situation where various natural products are used.
<실시예 1> 박하 발효 추출물의 물리 화학적인 성질Example 1 Physicochemical Properties of Peppermint Fermented Extract
박하 발효 추출물을 수용액으로 제조하여 비중, 굴절률, 건조잔분, pH, 중금속(납), 비소함량을 측정하였다.Peppermint fermentation extract was prepared as an aqueous solution to measure specific gravity, refractive index, dry residue, pH, heavy metal (lead), arsenic content.
이는 박하 발효 추출물을 이용하여 화장품 원료로 판매할 경우에 갖추어야 하는 항목이며 이들 중 중금속 및 비소함량이 가장 중요한 항목이다.This is an item to be equipped when selling as a cosmetic raw material using peppermint fermentation extract, and among these, heavy metal and arsenic content are the most important items.
비중(DFT)이라 함은 검체와 물과의 각각 t' ℃ 및 t ℃에 있어서 같은 체적의 중량비를 말한다.Specific gravity (DFT) refers to the weight ratio of the same volume at t '℃ and t ℃ between the sample and water, respectively.
비중부액계에 의한 측정법을 이용하여 비중부액계가 정지하였을 때 메니스커스의 상연에서 비중의 눈금을 측정하였으며 비중계는 대한계량기 제작소사의 비중계를 이용하여 측정하였다.The specific gravity scale was measured at the top of the meniscus when the specific gravity liquidimeter was stopped using the measurement method of the specific gravity liquidimeter, and the hydrometer was measured using the hydrometer of the Korean weighing machine.
물질의 굴절률은 진공 중의 광의 속도와 물질 중의 광의 속도와의 비율이며 물질에 대한 광의 입사각의 정현과 굴절각의 정현과의 비는 같다.The refractive index of the material is the ratio of the speed of light in the vacuum to the speed of light in the material and the ratio of the sine of the angle of incidence of the light to the material and the sine of the angle of refraction.
보통 굴절률은 광의 파장 및 온도에 따라 변화한다.Usually the refractive index changes with the wavelength and temperature of the light.
굴절률 n tD라 함은 광선으로 나트륨의 스펙트라 중 D선을 써서 온도 t ℃에서 측정하였을 때의 공기에 대한 굴절률을 말한다.The refractive index n tD refers to the refractive index with respect to air when measured at the temperature t ° C. using the D line of sodium spectra as a light ray.
본 실험에서는 NAR-1T(ATAGO CO.)를 이용하여 20 ℃에서 측정하였다.In this experiment, it was measured at 20 ℃ using NAR-1T (ATAGO CO.).
강열잔분시험법은 보통 유기물 중에 불순물로서 들어있는 무기물의 함량을 알기 위하여 적용되나 때에 따라서는 유기물중의 구성 성분으로서 들어있는 무기물 또는 휘발성무기물 중에 들어있는 불순물의 양을 측정하는데 적용된다.The ignition residue test is usually applied to determine the content of inorganic matter as an impurity in organic matter, but sometimes to measure the amount of impurities in inorganic or volatile inorganic matter as a constituent of organic matter.
그러나, 본 실험에서는 가혹조건은 500 ℃ 이상에서 수행하지 않고 일반적으로 적용되는 105 ℃에서 2시간 동안 가열하여 남은 잔분을 측정하였다.(Mettler LP16, TOLEDO Co.)However, in this experiment, the harsh conditions were not performed at 500 ° C. or higher, and the residual residue was measured by heating at 105 ° C. for 2 hours. (Mettler LP16, TOLEDO Co.)
pH 측정은 유리전극을 단 pH메터를 이용하여 표준완충용액을 쓰며 그 값을 ±0.02 이내로 정확도를 갖도록 하였다.(1% Soln., Model 420, ThermoOrion Co.)pH measurement was performed using a standard buffer solution using a pH meter with a glass electrode, and the value was accurate to within ± 0.02. (1% Soln., Model 420, ThermoOrion Co.)
비소시험법은 원료 중에 불순물로서 들어있는 비소의 한도시험을 의미한다.Arsenic test means a limit test of arsenic contained as impurities in raw materials.
그 한도는 삼산화비소(As203)의 양으로 나타내며, 보통 중량백만분률(ppm)로 나타낸다.The limit is expressed in terms of arsenic trioxide (As203), usually expressed in parts per million (ppm).
중금속 시험법은 원료 중에 불순물로서 들어있는 중금속의 한도시험이다.The heavy metal test is a limit test for heavy metals contained as impurities in raw materials.
중금속이란 산성에서 황화나트륨시액으로 정색하는 금속성 혼재물을 말하며 그 한도는 납(Pb)으로서 중량백만분률(ppm)로 나타낸다.Heavy metals refer to metallic mixtures that are acidic to sodium sulfide solution, the limits of which are expressed in parts per million (ppm) as lead (Pb).
상기 LOQ(Limit of Quantification), 즉 용액으로 하여 측정할 경우에 pb에 대하여 <7.0 ppb , As에 대하여 <11.0 ppb을 보이고 있다.The limit of quantification (LOQ), that is, when measured as a solution, shows <7.0 ppb for pb and <11.0 ppb for As.
즉, 상기 실험항목 중 가장 중요한 중금속이나 비소의 함량은 극히 낮은 량으로 검출되었다.
That is, the content of the most important heavy metals or arsenic of the experimental items was detected in an extremely low amount.
<실시예 2> 박하 발효 추출물의 일차 피부 자극 시험Example 2 Primary skin irritation test of peppermint fermentation extract
피부 일차 자극은 피부에 자극을 주는 물질의 1회 접촉에 의해 나타나는 급성 염증 또는 피부 괴사를 나타내며 1차 자극에서는 염증을 유발하지 않지만 반복 접촉에 의해 나타나는 경우는 누적 자극이라 한다.Dermal primary irritation refers to acute inflammation or skin necrosis caused by a single contact of a substance that irritates the skin. The primary irritation does not cause inflammation, but when caused by repeated contact, it is called a cumulative irritation.
1차 자극을 일으킬 수 있는 물질은 아주 많으며 강한 자극성을 나타내는 물질을 피부에 1회 적용함으로써 나타나며 인체 시험에서의 자극 또는 누적 자극을 예측하기 위한 수단으로 많이 쓰인다.There are many substances that can cause primary irritation, which is indicated by one-time application of strong irritant substances to the skin and used as a means of predicting stimulation or cumulative stimulation in human testing.
일반적으로 일차 자극 방법은 Draize 방법의 변형이 많이 쓰인다.In general, the primary stimulation method is a variation of the Draize method.
박하 발효 추출물의 pH 2 이하 또는 pH 11.5 이상의 경우에는 실험을 하지 않으며 피부 LD50이 200mg/kg 이상의 경우는 하지 않는다.Tests are not carried out for pH 2 or below 11.5 or above for peppermint fermentation extracts, and for skin LD50 of 200 mg / kg or more.
시험동물로 토끼를 선택하였으며 토끼는 의약품 및 화장품 신원료 개발에 널이 이용되고 있으며 생리, 해부 독성학적 기초 자료가 풍부하다.Rabbits were chosen as test animals, and rabbits are used for the development of new pharmaceutical and cosmetic raw materials and are rich in basic physiological and anatomical toxicological data.
주령은 6주령이며, 12마리를 실험하였다.The age was 6 weeks and 12 animals were tested.
약 7일간 검역 및 적응기간을 갖고 이 기간동안 체중 증가 및 일반 증상 등에 대하여 검사를 실시한다.During the seven days of quarantine and adaptation, weight gain and general symptoms are examined during this period.
시험 물질 적용 약 24시간 전에 토끼 등부위의 털을 가로, 세로 약 10cm 이상이 되도록 상처가 나지 않도록 제모기를 이용하여 제모하며 시험 동물은 등 부위에 찰과용 테이프를 이용하여 등 오른쪽 부위에 약 20mm x 20mm 크기의 찰과 부위를 만들며 찰과 부위에 대칭이 되도록 비찰과 부위를 두어 시험한다.About 24 hours before application of the test substance, the hair of the rabbit's hair is removed by a hair removal machine so that it does not hurt so that it is more than 10cm long and vertical.The test animal is about 20mm x on the right side of the back by using an abrasion tape on the back. Make a 20mm-sized scratch and site and test it by placing the mirror and site so that it is symmetrical.
패취 시험용 테이프에 시험물질 0.1ml를 도포한 후 각각 찰과, 비찰과 부위에 테이프를 부착한다.Apply 0.1 ml of the test substance to the patch test tape, and then attach the tape to the rub, non-crumb and areas.
테이프 부착 부위는 탈락되지 않도록 종이 테이프를 이용하여 고정한 후 탄력성이 있는 밴드를 이용하여 시험 부위 전체를 고정한 후 보정틀에서 24시간 동안 유지하여 준다.The tape attachment site is fixed with paper tape to prevent it from falling off, and then the entire test site is fixed with an elastic band and maintained in the calibration frame for 24 hours.
24시간이 경과한 후 패취를 제거하여 주며 시험물질이 잔류하지 않도록 생리식염수로 세정하여 준다.After 24 hours, the patch is removed and washed with physiological saline so that no test substance remains.
단일 농도 투여시에는 0.5ml 또는 0.5g을 투여량으로 한다.In the case of a single concentration administration, 0.5 ml or 0.5 g is used as a dose.
도포 후 24시간 및 72시간 후에 홍반 및 가피 형성 유무와 부종 형성 유무 등의 자극 유무를 평가하게 된다.24 hours and 72 hours after application, the presence of irritation such as erythema and skin formation and edema formation is evaluated.
각 동물의 피부 반응의 결과는 의약품등의독성시험기준의 피부반응의 평가기준에 따라 평점으로 평가한다.The result of skin reaction of each animal is evaluated by the score according to the evaluation criteria of skin response of toxicity test standard of medicines.
피부 일차 자극 지수(P.I.I)는 시험 물질 적용 후 24시간과 72시간 째의 홍반과 부종 평점에 의하여 산출한다.The skin primary irritation index (P.I.I) is calculated from erythema and edema grades at 24 and 72 hours after application of the test substance.
찰과 부위와 비찰과 부위 각각에 홍반 평점의 평균과 부종 평점의 평균을 구하여 24시간 째의 결과와 72시간 째의 결과의 평균값을 피부 일차 자극 지수로 한다.The mean value of erythema grade and edema grade in each of the abrasion site, the non-brain site, and the average area of the results at 24 hours and at 72 hours are used as the primary skin irritation index.
상기 표 4에 도시한 바와 같이 실험기간 중 특이한 임상 증상을 보이거나 사망한 토끼는 없었으며, 박하 추출물의 P.I.I는 0.188로 무자극 범위에 해당하였다.As shown in Table 4, there were no rabbits showing unusual clinical symptoms or death during the experiment, and the P.I.I of the peppermint extract was 0.188, corresponding to the non-irritating range.
또한, 10% 농도에서 물질 자체에 의한 착색이 있었으나 자극 평가에 영향을 줄 정도는 아니었다.
In addition, there was pigmentation by the substance itself at 10% concentration, but not enough to affect the stimulus evaluation.
<실시예 3> 박하 발효 추출물의 안점막 자극 시험Example 3 Ocular Mucosal Stimulation Test of Peppermint Fermentation Extracts
눈에 접촉할 가능성이 있으므로 안점막 자극 시험을 실시하는 것이다.Because of the potential for eye contact, eye mucosal irritation tests are performed.
각 동물의 안점막 반응의 자극 평가는 의약품등의독성시험기준의 안구병변의 등급을 이용하여 평가한다.Evaluation of the irritation of the ocular mucosa response of each animal is evaluated using the grade of eye lesions according to the toxicity test criteria, such as pharmaceuticals.
주령은 6주령이며, 18마리를 실험하였다.
The age was 6 weeks and 18 animals were tested.
NWA )는 non-washing이며, WB )는 washing을 의미한다.NW A ) is non-washing and W B ) means washing.
추출물을 투여한 후 1, 24, 48, 72시간째에 시험물질 적용부위를 관찰하여 각막의 혼탁 및 혼탁된 각막의 범위, 홍채의 반응, 결막의 발적, 부종 및 배설물 유무 등의 변화를 육안으로 관찰하였다.At 1, 24, 48, and 72 hours after administration of the extract, the application site of the test substance was observed. Observed.
Rating
A.O.Ia )(Acute ocular irritation index) : Max. Among M.O.IAOI a ) (Acute ocular irritation index): Max. Among MOI
M.O.Ib )(Mean ocular irritation index) : Total score/tested animal NO. In each observation timeMOI b ) (Mean ocular irritation index): Total score / tested animal NO. In each observation time
Day 7 I.O.Ic )(Individual ocular irritation index) : score of each animal on Day-7Day 7 IOI c ) (Individual ocular irritation index): score of each animal on Day-7
M.O.Ia ) (Mean ocular irritation index) : Total score/tested animal NO. In each observation timeMOI a ) (Mean ocular irritation index): Total score / tested animal NO. In each observation time
A.O.Ib ) (Acute ocular irritation index) : Max. Among M.O.IAOI b ) (Acute ocular irritation index): Max. Among MOI
상기 자극 결과(A.O.Ib ))는 0.5로 practically non irritant를 나타내었다.The stimulus result (AOI b ) was 0.5, indicating a practically non irritant.
따라서, 사용이 가능한 추출물임을 알 수 있었다.
Thus, it was found that the extract can be used.
<실시예 4> 박하 발효 추출물의 단회투여경구시험Example 4 Single-Dose Oral Test of Peppermint Fermentation Extracts
종 및 계통은 ICR 마우스이며, 주령은 4~5주령이고 사용 수는 암컷 5마리, 수컷 5마리이다.Species and strains are ICR mice, 4-5 weeks old, with 5 females and 5 males.
2 g / kg
Water
Water
2 g / kg
상기한 바와 같이 단회투여경구독성으로 인한 어떠한 이상 증상도 나타나지 않았으며, LD50이 2 g/kg 이상으로 단회투여경구독성 측면에서 안전한 추출물임을 알 수 있었다.
As described above, no abnormal symptoms caused by single dose oral toxicity were not observed, and it was found that LD50 was a safe extract in terms of single dose oral toxicity at 2 g / kg or more.
<실시예 5> 박하 발효 추출물의 세포재생효과 분석Example 5 Analysis of Cell Regeneration Effect of Peppermint Fermentation Extract
본 발명의 박하 발효 추출물이 주름개선 효과가 있는지 알아보기 위해 피부세포에 박하 발효 추출물을 농도별로 처리하여 피부세포의 증식에 미치는 영향을 분석하였다.In order to find out whether the peppermint fermentation extract of the present invention has an anti-wrinkle effect, the effect of the peppermint fermentation extract on the skin cells by concentration was analyzed.
구체적으로, T-75 플라스크에 인간섬유아세포(HNF, Normal HumanSpecifically, human fibroblasts (HNF, Normal Human) in a T-75 flask
Fibroblast)(CCD-986K, KCLB 21947)를 배양한뒤 1 ×PBS로 2-3회 세척하고, 0.025% Trypsin-EDTA를 처리하여 플라스크에 부착된 세포를 떨어뜨렸다. Fibroblast) (CCD-986K, KCLB 21947) was incubated with 1 × PBS 2-3 times, and treated with 0.025% Trypsin-EDTA to drop the cells attached to the flask.
상기 세포를 수득해 1500 rpm에서 5분간 원심분리(Heraeus, Labofuge 400R)한 후, 세포로 이루어진 펠렛(pellet)을 10 ㎖의 DMEM(5% FBS 포함)에 부유시켰다. 헤마사이토미터(Heamacytometer)를 이용하여 세포수를 측정한 뒤 2 ×103 정도의 세포를 96웰 플레이트의 각 웰에 200 ㎕씩 분주하였다. The cells were obtained and centrifuged at 1500 rpm for 5 minutes (Heraeus, Labofuge 400R), and then pelleted cells were suspended in 10 ml of DMEM (including 5% FBS). After measuring the number of cells by using a hematocytometer (Heamacytometer), the cells of about 2 × 103 was dispensed into each well of 200 well each 96 well plate.
웰 면적의 약 50% 정도로 세포가 자라면 새로운 DMEM(2% FBS 포함) 배지로 교환해 주면서, 본 발명의 박하 발효 추출물을 1,000, 500, 250, 125, 62.5 ppm의 농도로 각 웰에 첨가하여 37℃, 5% CO2에서 세포를 배양하였다.When cells grow to about 50% of the well area, the peppermint fermentation extract of the present invention is added to each well at concentrations of 1,000, 500, 250, 125, and 62.5 ppm while exchanging with fresh DMEM (containing 2% FBS) medium. Cells were incubated at 37 ° C., 5% CO 2.
본 발명의 추출물을 첨가하여 배양한지 3일 후에 세포의 재생효과를 측정하기 위해 MTT(3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide) 분석을 하였다. Three days after incubation with the addition of the extract of the present invention, MTT (3- (4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide) analysis was performed to determine the regeneration effect of the cells.
MTT(Sigma)를 PBS에 2 ㎎/㎖ 농도가 되도록 용해시킨 후 세포 배양배지 부피의 10%(20 ㎕)를 처리하고, 2시간 더 세포를 배양하였다. MTT (Sigma) was dissolved in PBS at a concentration of 2 mg / ml, 10% (20 μl) of the cell culture medium was treated, and the cells were further incubated for 2 hours.
배양한 세포의 상등액을 버리고 난 뒤, 150 ㎕의 DMSO를 넣어주어 잘 섞어주거나 또는 0.04 N HCl(in acid-isopropanol) 100 ㎕를 넣은 후 섞어주었다. After discarding the supernatant of the cultured cells, add 150 μl of DMSO and mix well or add 100 μl of 0.04 N HCl (in acid-isopropanol) and mix.
상기 과정이 끝난 후 ELISA 판독기(μQuant, Bio-Tek instrument INC.)를 이용해 560 nm에서 흡광도를 측정하였다(Reference : 650nm).After the procedure, the absorbance was measured at 560 nm using an ELISA reader (μQuant, Bio-Tek instrument INC.) (Reference: 650 nm).
도 1에 도시한 바와 같이, 선퇴의 경우에는 세포재생효과가 거의 없는 것으로 알 수 있었으며, 박하가 500~62.5ppm의 농도에서 30~50%의 재생효과를 보였으며, 강활의 경우에는 500~62.5ppm의 농도에서 10~30%의 재생효과를 보였다.As shown in Figure 1, it was found that there is little cell regeneration effect in the case of sediment, the mint showed a regeneration effect of 30 to 50% at a concentration of 500 ~ 62.5ppm, 500 ~ 62.5 in the case of vigor Regeneration effect of 10-30% was shown at the concentration of ppm.
이는 다른 물질이 섬유 아세포를 20 내지 30%로 증식시키는 효과를 나타내는것에 비하면 전례를 찾기 힘들 정도의 뛰어난 증식효과이다.
This is an unparalleled proliferative effect compared to other substances that have the effect of proliferating fibroblasts by 20-30%.
<실시예 6> 박하 발효 추출물의 단백질 분해효소 억제기능 분석Example 6 Analysis of Protease Inhibitory Function of Peppermint Ferment Extract
Extracelluar matrix의 주요 성분인 콜라겐을 분해하는 활성화된 단백질 분해효소의 하나인 matrix metalloproteinase(MMP)를 이용한 실험을 수행하였다.An experiment was performed using matrix metalloproteinase (MMP), an activated protease that degrades collagen, a major component of the extracelluar matrix.
단백질의 항원-항체 반응에 의해 콜라겐나제의 발현량을 확인하는 방법으로 western blot과 immuno assay 방법이 있다.Western blot and immunoassay methods are used to confirm the expression level of collagenase by antigen-antibody reactions of proteins.
상기 방법은 발현량을 보는 것(MMP-1)이고 이들 뿐만 아니라, 단백질의 활성을 확인할 필요가 있어 zymography 방법(MMP-2)으로 실험하였다.The method was to look at the expression level (MMP-1) and, as well as these, it was necessary to confirm the activity of the protein was tested by the zymography method (MMP-2).
즉, Normal Human Fibroblast에 UVA를 쪼여준 후 UVA에 의한 procollagen의 감소 및 MMP의 발현 증가에 대한 추출물의 억제 효과를 확인하고자 하였다.In other words, the effect of the extract on the decrease of procollagen and the increase of MMP expression by UVA after UVA was injected into Normal Human Fibroblast.
같은 protein 양을 로딩할 수 있도록 조절을 해서 본 발명의 샘플과 같은 부피의 샘플 버퍼(2X)를 혼합하여 실온에서 10분간 둔다.Adjust to load the same amount of protein, mix the same volume of sample buffer (2X) of the sample of the present invention and leave for 10 minutes at room temperature.
pre-casting gel을 이용하여 웰에 로딩하고, 125v constant voltage에서 약 90분간 gel running을 한다.Load into the well using a pre-casting gel, and run the gel for about 90 minutes at 125v constant voltage.
이후, Novex Zymogram Renaturing Buffer(1X) 100ml에 한판 또는 두판의 젤을 약하게 흔들어주면서 30분간 넣어둔다.Subsequently, in a 100ml Novex Zymogram Renaturing Buffer (1X), gently shake the gel of one or both plates for 30 minutes.
Novex Zymogram Developing Buffer(1X)로 바꾸어서 약 1시간 가량 흔들어준다.Change to Novex Zymogram Developing Buffer (1X) and shake for about 1 hour.
새로운 Developing Buffer로 바꾼 후 37℃에서 밤새 놓아둔다.Change to a new Developing Buffer and leave at 37 ° C overnight.
Commassie Blue R-250 solution (dye 50 mg, MeOH 22.5 ml, DIW 22.5 ml, glacial acetic acid 5 ml)으로 염색한다.Stain with Commassie Blue R-250 solution (dye 50 mg, 22.5 ml MeOH, 22.5 ml DIW, 5 ml glacial acetic acid).
destaing solution(MeOH 5 ml, glacial acetic acid 5 ml, DIW 40 ml)으로 탈색한다.Decolorize with destaing solution (5 ml of MeOH, 5 ml of glacial acetic acid, 40 ml of DIW).
드라이 킷을 이용하여 기포가 없도록 주의하여 말린다.Use a dry kit to dry carefully to avoid bubbles.
도 2에 도시한 바와 같이, MMP-2(Zymography)실험 결과 대조 샘플과 비교하여 MMP2 발현 및 활성 감소에 있어 모든 시료(박하, 강활, 선퇴)가 효과가 없는 것으로 확인하였다.As shown in Figure 2, MMP-2 (Zymography) experiments as compared to the control sample was confirmed that all the samples (mint, vigor, degeneration) in the MMP2 expression and activity reduction is ineffective.
도 3에 도시한 바와 같이, MMP-1의 발현량과 procollagen 실험 결과 박하가 UVA에 의한 MMP-1의 발현 증가를 억제시키는 효과가 있음을 확인하였으며, procollagen은 모든 시료에서 효과가 없었다.As shown in Figure 3, MMP-1 expression and procollagen experiments were confirmed that peppermint has an effect of inhibiting the expression of MMP-1 by UVA, procollagen was not effective in all samples.
한편, 인중합체(polyphosphate)는 두 개 이상의 인산염이 수십개 내지 수백개 연결되어 오르소포스페이트(orthophosphate, Pi)를 이루고 있는 인산염의 선형 중합체를 말하는 것으로서, 인중합체 분자의 각 결합은 고에너지 무수인산염(phosphoanhydride) 결합으로 이루어져 있다. Meanwhile, polyphosphate refers to a linear polymer of phosphates in which two or more phosphates are connected to dozens or hundreds of phosphates to form orthophosphate (Pi), and each bond of the phosphate molecule is a high energy anhydrous phosphate ( phosphoanhydride).
이러한 인중합체의 사슬 말단은 P-AMP 포스포트랜스퍼라제, 인중합체 키나아제, 인중합체 글루코키나아제 및 엑소폴리포스파타아제의 촉매작용에 의하여 각각 AMP, ADP, 포도당 또는 물에 의한 공격을 받으며, 내부적으로는 엔도폴리포스파타아제에 의하여 공격을 받는다.The chain ends of these inpolymers are attacked by AMP, ADP, glucose or water, respectively, by the catalysis of P-AMP phosphotransferase, inpolymer kinase, inpolymer glucokinase and exopolyphosphatase, and internally. Is attacked by endopolyphosphatase.
이러한 인중합체 분자는 음이온가가 높은 상태이므로 코발트, 구리, 마그네슘, 칼슘, 철, 아연 등과 같은 다가 양이온과 견고하게 결합할 수 있는데, 상기 특성으로 인하여 정상적인 미생물 대사를 통해 취하여야 할 물질들이 안정적으로 결합할 수 있어서 결국 미생물의 성장에 저해요인이 되는 것으로 알려져 있다. Since these inpolymer molecules have a high anion state, they can bind firmly to polyvalent cations such as cobalt, copper, magnesium, calcium, iron, and zinc. Due to this property, substances to be taken through normal microbial metabolism can be stably bound. It is known that it can eventually inhibit the growth of microorganisms.
인중합체는 식용육류와 치즈의 발색 촉진제 및 첨가제, 통조림의 응유제거제, 다양한 탄산수 첨가물, 치양 및 위장약 등에 사용되고 있으며, 미국의 FDA와 농무부(Department of Agriculture)에서 인체에 무해한 물질로 공인받은 바 있다. Phosphorus polymers are used in food and cheese color promoters and additives, canned milk curds, various carbonated water additives, hemorrhoids and gastrointestinal drugs, and have been certified as harmless to the human body by the US FDA and the Department of Agriculture.
통상적으로 항산화제로 많이 사용되는 비타민 C, 비타민 E 등은 여러 제형에서 물이나 빛에 의하여 변색되는 등의 한계가 있어 그 사용량이 극히 제한되어 왔다. Vitamin C, vitamin E, and the like, which are commonly used as antioxidants, have limitations such as discoloration due to water or light in various formulations, and their amount of use has been extremely limited.
인중합체는 이러한 종래의 항산화제가 갖는 제형의 한계를 극복할 수 있기 때문에 각종 항산화용 화장품에 유용하게 이용될 수 있다.Phosphorus polymers can be usefully used in various antioxidant cosmetics because they can overcome the limitations of the formulations of the conventional antioxidants.
또한, 본 발명의 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품에 있어서, 인중합체는 과산화 저해 활성 및 라디칼 제거 활성이 우수하여 높은 항산화 활성을 가지므로, 피부의 과산화 예방을 위해 유용하게 사용될 수 있다. In addition, in the functional cosmetics for improving skin wrinkles containing the phosphorus polymer contained in the peppermint fermentation extract of the present invention as an active ingredient, the phosphorus polymer has a high antioxidant activity and excellent anti-oxidation inhibitory activity and radical scavenging activity, It can be usefully used to prevent peroxidation.
따라서, 인중합체는 피부 노화 억제, 피부 탄력 유지 또는 주름 개선을 위한 화장품 시료로서 이용될 수 있으며, 바람직하게는 유연화장수, 영양화장수, 영양크림, 엣센스, 팩 또는 목욕용 파우더의 기초 화장품 시료로서 이용될 수 있다.Therefore, the inpolymer may be used as a cosmetic sample for inhibiting skin aging, maintaining skin elasticity or improving wrinkles, and is preferably used as a basic cosmetic sample of softening cream, nutrient cream, nourishing cream, essence, pack or bath powder. Can be.
본 발명의 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품에 있어서, 통상적으로 함유되는 화장품 조성물에 인중합체가 0.0001 내지 20 중량부, 바람직하게는 0.001 내지 10 중량부의 양으로 첨가된다.In functional cosmetics for improving skin wrinkles containing an inpolymer contained in the peppermint fermentation extract of the present invention as an active ingredient, 0.0001 to 20 parts by weight, preferably 0.001 to 10 parts by weight of the inpolymer in the cosmetic composition Is added in amounts.
표 11에 도시한 바와 같이, 본 발명의 박하는 다른 한약재보다 인중합체(polyphosphte)가 많이 함유되어 있음을 확인할 수 있었다.As shown in Table 11, it was confirmed that the mint of the present invention contained more polyphosphate than other herbal medicines.
한편, 상기 박하보다 선퇴가 인중합체의 함량이 높은 것으로 나타났지만, 도 1에 도시한 바와 같이 세포재생효과에서는 박하보다 떨어지므로 박하의 인중합체를 유효성분으로 하는 화장품을 제조할 경우에 선퇴보다는 훨씬 세포 재생 효능이 좋게 된다.
On the other hand, it is shown that the content of the inpolymer is higher than the mint, but in the cell regeneration effect as shown in Figure 1 is lower than the mint in the case of manufacturing cosmetics using the inpolymer of the mint as an active ingredient much better than the selection Cell regeneration efficacy is good.
<실시예 7> 락토바실러스 애시도필러스를 이용한 박하 발효 추출물의 제조Example 7 Preparation of Peppermint Fermentation Extract Using Lactobacillus Ashdophilus
박하의 표면에 존재하는 이물질들을 제거하기 위하여 세척을 수행한 후 박하를 즉시 동결 건조시킨 후 동결 건조된 박하를 분쇄시키며 상기 분쇄된 박하 20g을 400 ㎖의 증류수에 넣고, 200℃에서 2시간 동안 열수 추출한 뒤 여과하였다. After washing to remove foreign substances present on the surface of the mint, the freeze-dried peppermint is immediately dried, and the freeze-dried peppermint is pulverized. 20 g of the ground peppermint is put in 400 ml of distilled water and hot water at 200 ° C. for 2 hours. Extracted and filtered.
상기 여과된 박하 추출물을 50 내지 70℃에서 감압농축하고 최종 농축액이 40 ㎖이 되도록 맞춘 후 이를 여과하여 박하 추출물로 제조하였다.The filtered peppermint extract was concentrated under reduced pressure at 50 to 70 ° C., the final concentrate was adjusted to 40 ml, and then filtered to prepare a peppermint extract.
상기 추출된 박하 추출물을 10g/L되게 락토바실러스 애시도필러스 (Lactobacillus acidophilus) 배양액에 첨가하였다. The extracted peppermint extract was added to the Lactobacillus acidophilus culture to 10g / L.
여기에 탄소원으로 덱스트로즈와 pH조절제로 디포타슘 포스페이트 (Dipotassium phosphate)를 첨가하였다. Dextrose as a carbon source and dipotassium phosphate as a pH adjuster were added thereto.
이때 사용한 균주로는 락토바실러스 애시도필러스(Lactobacillus acidophilus)를 사용하였으며, 배양액당 50,000 cfu/L로 첨가하였다. The strain used was Lactobacillus acidophilus (Lactobacillus acidophilus) was used, and was added at 50,000 cfu / L per culture.
배양은 발효조를 이용하여 10일간, 35℃, pH 5-7로 유지하며 배양하였다. The culture was carried out using a fermenter for 10 days, maintained at 35 ℃, pH 5-7.
배양 후 배양액을 원심분리하여 배양균을 1차 제거한 후 여과기를 이용하여 최종 여과하였다. After incubation, the culture solution was centrifuged to remove the culture cells first, and then filtered through a filter.
이렇게 얻은 여과액을 다시 4℃의 저온 창고에서 약 10일간 숙성시킨 후 액을 다시 여과기를 이용하여 여과하여 최종 박하 발효액을 획득하게 되며 이를 화장품의 제조에 사용하게 된다.The filtrate thus obtained is aged again for about 10 days in a low temperature warehouse at 4 ° C., and the filtrate is filtered again using a filter to obtain a final peppermint fermentation broth, which is used in the manufacture of cosmetics.
<제조예 1> 박하 발효 추출물을 이용한 화장품의 제조Preparation Example 1 Preparation of Cosmetics Using Mint Fermented Extract
본 발명의 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품은 일반적인 유화 제형 및 가용화 제형의 형태로 제조할 수 있다. Functional cosmetics for improving skin wrinkles containing the inpolymer contained in the peppermint fermentation extract of the present invention as an active ingredient can be prepared in the form of a general emulsion formulation and solubilized formulation.
본 발명의 바람직한 제조예에서는 박하 발효 추출물을 이용하여 영양화장수, 크림, 에센스 등의 유화 제형의 화장품, 유연화장수와 같은 가용화 제형의 화장품을 제조하였다. In a preferred manufacturing example of the present invention using the peppermint fermentation extract was prepared cosmetics of solubilized formulations, such as cosmetics, emulsified cosmetics, such as nutrient cosmetics, creams, essences, emulsion formulations.
유화 제형은 박하 발효 추출물을 전체 화장품 중량부에 대해 50 중량부를 함유하도록 제조하였으며, 가용화 제형은 박하 발효 추출물을 전체 화장품 중량에 대해 20 중량부를 함유하도록 제조하는 것이 피부 노화의 가장 큰 원인인 UV에 대하여 콜라겐을 보호하는 효과(특히, 염증을 억제시키는 효과)가 뛰어나기 때문에 상기한 중량부를 유지하는 것이 바람직하다.
Emulsified formulations were prepared to contain 50 parts by weight of peppermint fermentation extract based on the total weight of cosmetics, and solubilized formulations were prepared to contain 20 parts by weight of peppermint fermentation extract relative to the total weight of cosmetics. Since it is excellent in the effect of protecting collagen (particularly, the effect of suppressing inflammation), it is preferable to maintain the above-mentioned parts by weight.
<1-1> 유화 제형의 화장품 제조<1-1> Cosmetic Preparation of Emulsifying Formulations
제조 방법은 하기와 같다.The production method is as follows.
1) 스테아린산 0.3 중량부, 스테알리 알콜 0.2 중량부, 글리세릴 모노스테아레이트 1.2 중량부, 밀납 0.4 중량부, 폴리옥시에틸렌솔비탄 모노라우린산 에스테르 2.2 중량부, 파라옥시안식향산 메틸 0.1 중량부, 파라옥시안식향산 프로필 0.05 중량부, 세틸에틸헥사노에이트 5 중량부, 트리글리세라이드 2 중량부를 혼합한 1차 혼합물을 60∼80℃로 가열하였다.1) 0.3 parts by weight of stearic acid, 0.2 parts by weight of steali alcohol, 1.2 parts by weight of glyceryl monostearate, 0.4 parts by weight of beeswax, 2.2 parts by weight of polyoxyethylene sorbitan monolauric acid ester, 0.1 parts by weight of methyl paraoxybenzoate, The primary mixture of 0.05 parts by weight of paraoxybenzoic acid profile, 5 parts by weight of cetylethylhexanoate and 2 parts by weight of triglyceride was heated to 60 to 80 ° C.
2) 이후, 사이클로메티콘 3 중량부를 상기 1차혼합물에 투입하여 2차 혼합물을 제조하였고, 2) Then, 3 parts by weight of cyclomethicone was added to the primary mixture to prepare a secondary mixture.
3) 증류수 100 중량부, 농글리세린 5 중량부, 트리에탄올아민 0.15 중량부를 혼합한 혼합물을 65∼70℃로 가열하여 완전히 용해시키는 용해단계를 거치게 된다.3) A mixture of 100 parts by weight of distilled water, 5 parts by weight of concentrated glycerin, and 0.15 parts by weight of triethanolamine is heated to 65-70 ° C. to undergo a dissolution step for complete dissolution.
4) 상기 용해단계를 거치면서 상기 2)의 2차 혼합물을 서서히 첨가하여 8,000 rpm에서 2∼3분간 유화시켰다.4) During the dissolution step, the secondary mixture of 2) was slowly added to emulsify for 2-3 minutes at 8,000 rpm.
5) 폴리아크릴산 중합체 0.12 중량부를 물에 용해시킨 후 상기 4)의 혼합물에 첨가하고 2분간 더 유화시켰다.5) 0.12 parts by weight of a polyacrylic acid polymer was dissolved in water, and then added to the mixture of 4) and emulsified for 2 minutes.
6) 색소 0.0001 중량부, 향 0.1 중량부, 박하 발효 추출물 50 중량부를 상기 5)의 혼합물에 넣고 1분간 더 유화시켰다.6) 0.0001 parts by weight of pigment, 0.1 parts by weight of fragrance, 50 parts by weight of peppermint fermentation extract was added to the mixture of 5) and emulsified for 1 minute.
7) 상기 6)의 혼합물을 유화 후 탈기 과정을 거쳐 25∼35℃로 냉각시킴으로서 유화제형의 주름 개선 효과가 높은 화장품을 제조하였다.
7) By cooling the mixture of 6) through a degassing process and then cooled to 25 ~ 35 ℃ to prepare a cosmetic having a high wrinkle-improving effect of the emulsifier type.
<1-2> 가용화 제형의 화장품 제조<1-2> Cosmetic preparation of solubilized formulation
제조 방법은 하기와 같다.The production method is as follows.
1) 농글리세린 3 중량부, 1,3-부틸렌글리콜 2 중량부, EDTA-2Na 0.01 중량부, 색소 0.0002 중량부, 박하 발효 추출물 20 중량부를 정제수 100 중량부에 넣고 아직믹서를 이용하여 용해시켰다.1) 3 parts by weight of concentrated glycerin, 2 parts by weight of 1,3-butylene glycol, 0.01 part by weight of EDTA-2Na, 0.0002 part by weight of pigment, and 20 parts by weight of peppermint fermented extract were added to 100 parts by weight of purified water and dissolved using a still mixer. .
2) 파라옥시안식향산 메틸 0.1 중량부, 폴리옥시에틸렌 하이드로제네이디트 에스테르 0.3 중량부, 향 0.15 중량부, 사이클로메티콘 0.2 중량부를 알코올(95%) 8 중량부에 넣고 완전용해시켰다.2) 0.1 part by weight of methyl paraoxybenzoate, 0.3 part by weight of polyoxyethylene hydrogenate ester, 0.15 part by weight of fragrance, and 0.2 part by weight of cyclomethicone were added to 8 parts by weight of alcohol (95%) and completely dissolved.
3) 상기 2)의 혼합물을 상기 1)의 혼합물에 서서히 첨가하면서 가용화시켜 가용화 제형의 주름 개선 효과가 높은 화장품을 제조하였다.3) The mixture of 2) was solubilized by slowly adding to the mixture of 1) to prepare a cosmetic having a high anti-wrinkle effect of the solubilized formulation.
이상에서와 같은 내용의 본 발명이 속하는 기술분야의 당업자는 본 발명의 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시 예들은 모든 면에서 예시된 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. It will be appreciated by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. Therefore, the above-described embodiments are to be understood as illustrative in all respects and not restrictive.
본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허청구범위에 의하여 나타내어지며, 특허청구 범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.
The scope of the invention is indicated by the following claims rather than the above description, and all changes or modifications derived from the meaning and scope of the claims and their equivalents should be construed as being included in the scope of the invention. do.
Claims (5)
상기 동결 건조된 박하를 50메쉬 이상의 분말 상태로 분쇄하는 분쇄단계와;
상기 분말화된 박하를 증류수에 넣고, 100 내지 200℃ 추출온도에서 약 2 시간 동안 열수 추출하는 열수추출단계와;
여과된 박하 추출물을 50 내지 70℃에서 감압농축하고 최종 농축액을 수득하는 감압농축단계와;
락토바실러스 애시도필러스를 이용하여 상기 수득된 박하 추출물을 배양하여 박하 발효액을 제조하는 단계;로 구성되되, 박하 발효 추출물의 함량은,
화장품 총 중량을 기준으로 0.001 내지 50중량부인 것을 특징으로 하는 박하 발효 추출물에 포함된 인중합체를 유효성분으로 함유하는 피부 주름개선용 기능성 화장품.
A lyophilization step of washing the mint to remove foreign substances, etc. present on the surface of the material, and then lyophilizing the mint;
Grinding the freeze-dried peppermint into a powder state of 50 mesh or more;
Putting the powdered mint in distilled water and extracting hot water for about 2 hours at an extraction temperature of 100 to 200 ° C .;
Concentration of the filtered peppermint extract under reduced pressure at 50 to 70 ° C. to obtain a final concentrate;
Cultivating the obtained peppermint extract using Lactobacillus ashidophilus to prepare a peppermint fermentation broth; wherein the content of the peppermint fermentation extract is
Functional cosmetics for improving skin wrinkles containing the phosphorus as an active ingredient contained in the peppermint fermentation extract, characterized in that 0.001 to 50 parts by weight based on the total weight of the cosmetic.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100051457A KR101280481B1 (en) | 2010-05-31 | 2010-05-31 | Cosmetic for Improving Skin Wrinkle Comprising polyphosphate of fermented peppermint. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100051457A KR101280481B1 (en) | 2010-05-31 | 2010-05-31 | Cosmetic for Improving Skin Wrinkle Comprising polyphosphate of fermented peppermint. |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110131820A KR20110131820A (en) | 2011-12-07 |
KR101280481B1 true KR101280481B1 (en) | 2013-07-01 |
Family
ID=45500124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100051457A KR101280481B1 (en) | 2010-05-31 | 2010-05-31 | Cosmetic for Improving Skin Wrinkle Comprising polyphosphate of fermented peppermint. |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101280481B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015163589A1 (en) * | 2014-04-24 | 2015-10-29 | 주식회사 아모레퍼시픽 | Cosmetic composition containing mentha haplocalyx as active ingredient |
KR102174660B1 (en) | 2020-08-20 | 2020-11-05 | (주)브이에스신비 | Cosmetic Composition Comprising Fermented Liquor and Powder of Natural Plant and Preparation Methods Thereof |
KR102176938B1 (en) | 2020-08-20 | 2020-11-10 | (주)브이에스신비 | Cosmetic Composition Comprising Fermented Liquor of Natural Plant and Preparation Methods Thereof |
KR102303400B1 (en) | 2021-04-06 | 2021-09-24 | (주)브이에스신비 | Preparation Methods of Fermentation Products Using JEJU Lava Seawater, JEJU Barley Yeast and Natural Plant and Cosmetic Compositions Having Thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102232341B1 (en) * | 2019-02-12 | 2021-03-26 | 우석대학교 산학협력단 | Cosmetic composition for preventing or improving skin aging or skin inflammation comprising fermented product of Mentha piperascens leaf and ginger as an active ingredient |
KR102348714B1 (en) * | 2019-08-22 | 2022-01-06 | 재단법인 남원시화장품산업지원센터 | A cosmetic composition for antioxidant and wrinkle improvement containing a mixed extract comprising Sorbus commixta branch, Sorbus commixta fruit, Elsholtzia splendens flower and Taraxacum coreanum flower extract |
KR102348698B1 (en) * | 2019-08-22 | 2022-01-06 | 재단법인 남원시화장품산업지원센터 | Antioxidant and moisturizing cosmetic composition containing mixed extracts including Prunus yedoensis flower, Peach tree flower and Chrysanthemum flower extract |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089499A1 (en) * | 2002-01-15 | 2005-04-28 | Philippe Moussou | Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts |
KR100592513B1 (en) * | 2003-06-12 | 2006-06-23 | 김홍렬 | Pharmaceutical composition or health food having antioxidizing activity comprising polyphosphate as active ingredient |
KR20070073305A (en) * | 2006-01-04 | 2007-07-10 | 바이오스펙트럼 주식회사 | A composition for improving wrinkle on skin comprising plant extracts |
-
2010
- 2010-05-31 KR KR1020100051457A patent/KR101280481B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089499A1 (en) * | 2002-01-15 | 2005-04-28 | Philippe Moussou | Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts |
KR100592513B1 (en) * | 2003-06-12 | 2006-06-23 | 김홍렬 | Pharmaceutical composition or health food having antioxidizing activity comprising polyphosphate as active ingredient |
KR20070073305A (en) * | 2006-01-04 | 2007-07-10 | 바이오스펙트럼 주식회사 | A composition for improving wrinkle on skin comprising plant extracts |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015163589A1 (en) * | 2014-04-24 | 2015-10-29 | 주식회사 아모레퍼시픽 | Cosmetic composition containing mentha haplocalyx as active ingredient |
KR102174660B1 (en) | 2020-08-20 | 2020-11-05 | (주)브이에스신비 | Cosmetic Composition Comprising Fermented Liquor and Powder of Natural Plant and Preparation Methods Thereof |
KR102176938B1 (en) | 2020-08-20 | 2020-11-10 | (주)브이에스신비 | Cosmetic Composition Comprising Fermented Liquor of Natural Plant and Preparation Methods Thereof |
KR102303400B1 (en) | 2021-04-06 | 2021-09-24 | (주)브이에스신비 | Preparation Methods of Fermentation Products Using JEJU Lava Seawater, JEJU Barley Yeast and Natural Plant and Cosmetic Compositions Having Thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20110131820A (en) | 2011-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101280481B1 (en) | Cosmetic for Improving Skin Wrinkle Comprising polyphosphate of fermented peppermint. | |
US10092493B2 (en) | Composition of skin external application for anti-aging | |
KR101224697B1 (en) | Bioactive compositions from theacea plants and processes for their production and use | |
KR20090081178A (en) | Cosmetic composition containing wild flower extracts | |
KR102292975B1 (en) | Cosmetic materials composition for skin anti-wrinkling and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof | |
KR101917645B1 (en) | Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract | |
KR101078888B1 (en) | A cosmetic composition comprising tissue cultured Echinaceae adventitious roots and an preparing method thereof | |
KR101280482B1 (en) | Cosmetic for Improving Skin Wrinkle Comprising polyphosphate of fermented Chrysanthemum indicum . | |
KR102628844B1 (en) | Cosmetic composition for anti-oxidation, skin whitening and anti-wrinkle containing a mixed fermentation extracts of Wisteria floribunda flowers, Aralia elata flowers, Camellia japonica leafs and Camellia japonica flowers as effective component | |
US10973755B2 (en) | Method for treating skin aging and photodamage by using Camellia sinensis callus extract | |
KR102063686B1 (en) | Skin external composition containing extract of soybean root | |
KR102037927B1 (en) | Cosmetic composition composed of including extracts of drynaria fortunei and cosmetics using the same | |
KR102632084B1 (en) | Cosmetic composition for anti-oxidation, skin whitening, and improving of skin wrinkle containing Sanguisorba officinalis extract | |
KR100710657B1 (en) | Whitening cosmetic composition containing dihydroquercetin | |
KR19990086516A (en) | Anti-aging cosmetic composition containing ginseng extract | |
KR101904215B1 (en) | A composition for antioxidating and blocking ultraviolet comprising extracts of jujube seed | |
KR101142977B1 (en) | Cosmetic Composition Comprising Opuntia Five Element Tea Mixed Extract For Improving Atopic skin And Manufacturing Method Thereof And Cosmetic Material Containing The Same | |
KR101552472B1 (en) | Method for producing Crassostrea gigas extract with increased antioxidant and whitening activity | |
KR20200049714A (en) | Cosmetic composition for skin cooling or improving skin redness with the extract of Eucommia Ulmoides bark | |
KR101280483B1 (en) | Cosmetic for Improving Skin Wrinkle Comprising polyphosphate of fermented xanthium strumarium. | |
KR100440357B1 (en) | Cosmetic compositions containing levan | |
KR100864915B1 (en) | Composition comprising mixed extract of japanese apricot and pear blossom having anti-oxidative activity | |
KR101093901B1 (en) | A cosmetic composition comprising an extract of tissue cultured anoectochilus formosanus and a preparation method of the extract of tissue cultured anoectochilus formosanus | |
US20110178167A1 (en) | Method for inhibiting activity and/or expression of matrix metalloproteinase, inhibiting phosphorylation of mitogen-activated protein kinase, and/or promoting expression of collagen using terminalia catappa leaf extract | |
KR20130107123A (en) | Compositions containing extracts of glycine gracilis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160404 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180621 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190603 Year of fee payment: 7 |